MAGEA6 divergent transcript (MAGEA6-DT)

MAGEA6 divergent transcript (MAGEA6-DT) is a non-coding RNA gene, not a protein-coding gene or established therapeutic target[7]. Unlike the protein-coding MAGEA6 gene—which encodes an antigen relevant for cancer immunology and autophagy regulation—MAGEA6-DT is a distinct RNA entity likely named for its divergent (non-coding, possibly antisense or intergenic) transcript at or near the MAGEA6 gene locus[7]. There is currently a lack of experimentally validated information on the function, disease associations, or druggability of MAGEA6-DT. Existing literature and databases recognize it as a gene but do not characterize it as a target such as an enzyme, receptor, transporter, or component directly actionable by pharmacotherapy. If the intent is to refer to the protein-coding MAGEA6 ("Melanoma-associated antigen 6"), that is a validated target; however, MAGEA6-DT specifically refers to an RNA molecule and is not established as a therapeutic target. Note: - The abbreviation MAGEA6-DT and the term "divergent transcript" consistently refer to a non-coding RNA as catalogued in gene databases (e.g., GeneCards[7]). - There is currently no evidence for its classification as a receptor, enzyme, or any canonical therapeutic target, and no information on drugs, mechanisms, or biomarkers for this RNA transcript.[7] - If your interest was the protein-coding MAGEA6, see MAGEA6 for relevant therapeutic target information; otherwise, MAGEA6-DT, as an RNA, is not a defined pharmacological target.

Other names

MAGEA6 divergent transcriptMAGEA6-DT